Rising tennis star finishes treatment for Hodgkin's lymphoma
Young Russian tennis player Alisa Kleybanova has begun to train again after a diagnosis of Hodgkin's lymphoma briefly derailed her career.
The 22 year old Kleybanova was diagnosed with Hodgkin's in May of 2011. She underwent a protocol including combination chemotherapy, finishing her last treatment in December. Her most recent follow-up suggests they have been successful.
"More than anything, I've missed the competition,” she wrote at the WTA website. "For me the best part of tennis is the competition and I'm really looking forward to my comeback.”
Kleybanova has fourth round exits from both the Australian Open and Wimbledon, along with a pair of WTA Tour singles titles. She intends to make her return to the tennis circuit at a WTA tournament in March.
Source: Reuters
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
